High­land who? Biotech gets a $200M war chest to crack the US AD­HD mar­ket

At sev­er­al points last year, Toron­to-based High­land Ther­a­peu­tics spot­light­ed da­ta from a pair of piv­otal Phase III stud­ies of Ben­jor­na (HLD-200) which they say pro­vid­ed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.